share_log

Invitae Released A New Study In JAMA Network Open Clinical Practice Guidelines Recommend Genetic Testing Of All Patients With Breast Cancer

Invitae Released A New Study In JAMA Network Open Clinical Practice Guidelines Recommend Genetic Testing Of All Patients With Breast Cancer

Invitae在JAMA網絡上發佈的一項新研究開放臨牀實踐指南建議對所有乳腺癌患者進行基因檢測
Benzinga Real-time News ·  2022/09/22 11:02
Invitae study reports universal genetic testing improves outcomes for patients with breast cancer –
Invitae研究報告稱,通用基因檢測改善了乳腺癌患者的預後 –
SAN FRANCISCO, Sept. 22, 2022 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, released a new study in JAMA Network Open, underscoring the clinical utility of the American Society of Breast Surgeons (ASBrS) guidelines recommending universal genetic testing for patients with breast cancer, and showing universal testing improves patient outcomes. Building on a previous study reported in the Journal of Clinical Oncology, the current study is the first clinical outcomes study of a cohort of unselected patients with breast cancer who underwent universal germline genetic testing. Our data...
舊金山,9月2022年2月22日/美通社/--領先的醫學遺傳學公司Invitae(紐約證券交易所代碼:NVTA)在JAMA網絡開放強調了美國乳房外科學會(ASBRS)指南建議...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論